NIBRI Collaboration
"All in all, they [pathways] can provide a grammar applicable to drug discovery and medicine, from target validation through to the clinic."
Mark Fishman & Jeffrey Porter of Novartis in: 'A New Grammar for Drug Discovery',
Nature, vol. 437, 2005 [+]
Cellzome is a leader in the understanding of protein pathways in disease and how pharma- cologically active molecules act on these pathways. We are currently applying our » pathway expansion methodology to a large pan-therapeutic collaboration with Novartis Institutes for Biomedical Research Inc. (NIBRI).
Our Proteomics Pathway Group and NIBRI have already mapped the protein networks of several different signalling pathways implicated in various therapeutic areas. Many relevant protein interactors have been identified in each of the pathways, leading to a more thorough understanding of the molecular basis of the underlying diseases and novel target candidates.
Cellzome has characterised several Novartis compounds, using its » chemical proteomics methodology. Additionally, the collaboration team is providing more in depth functional analyses of target candidates and signalling aspects of the disease pathways.
« Back